Aqilion reports positive results from the ARIA-1 Phase 1 study in healthy subjects
· The drug candidate AQ280, an oral selective JAK1 inhibitor, was well tolerated, and the achieved single and multidose exposure is in line with estimates of a therapeutically effective range based on preclinical models · Pharmacokinetic data supports once daily dosing · Pharmacodynamic biomarker changes are consistent with JAK1 inhibition with no observed signs of JAK2 inhibition at the achieved exposuresAQILION (publ) reports positive results from its Phase 1 study ARIA-1 in healthy volunteers with the drug candidate AQ280, a selective proprietary JAK1 inhibitor, being developed as
